Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team. Keiser PH, et al. Among authors: pakes ge. BMC Infect Dis. 2005 Jan 12;5:2. doi: 10.1186/1471-2334-5-2. BMC Infect Dis. 2005. PMID: 15647105 Free PMC article. Clinical Trial.
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team. Kumar PN, et al. Among authors: pakes ge. HIV Med. 2006 Mar;7(2):85-98. doi: 10.1111/j.1468-1293.2006.00346.x. HIV Med. 2006. PMID: 16420253 Free article. Clinical Trial.
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team. Hicks CB, et al. Among authors: pakes ge. AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231. AIDS Res Hum Retroviruses. 2009. PMID: 19320570 Clinical Trial.
Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.
Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV. Sleasman JW, et al. Among authors: pakes ge. Clin Pharmacol Ther. 2009 Apr;85(4):394-401. doi: 10.1038/clpt.2008.236. Epub 2008 Dec 31. Clin Pharmacol Ther. 2009. PMID: 19118380 Free PMC article.
A review of the pharmacokinetics of abacavir.
Yuen GJ, Weller S, Pakes GE. Yuen GJ, et al. Among authors: pakes ge. Clin Pharmacokinet. 2008;47(6):351-71. doi: 10.2165/00003088-200847060-00001. Clin Pharmacokinet. 2008. PMID: 18479171 Review.
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW; AIDS Clinical Trials Group Protocol A5143 Team. Collier AC, et al. Among authors: pakes ge. HIV Clin Trials. 2008 Mar-Apr;9(2):91-102. doi: 10.1310/hct0902-91. HIV Clin Trials. 2008. PMID: 18474494 Clinical Trial.
63 results